Long-Term Dementia Risk in Parkinson Disease. Neurology. 2024 Sep 10;103(5):e209699 McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus ...

“After a recent diagnosis of Lewy Body Dementia (LBD) and Multiple System Atrophy (MSA), I am unable to perform at the level ...

Dementia with Lewy bodies (DLB) is a common neurodegenerative disorder in which patients exhibit symptoms of dementia and parkinsonism along with fluctuations and hallucinations that can be ...

The Penguin recently aired its sixth episode. The episode was filled with interesting twists and turns, leaving viewers on ...

This Centre’s research aims to address the cause, cure, care, and prevention of Lewy body dementia. By considering all elements of the disease, this Centre will pave the way for new treatments that ...

Nilotinib, a drug approved by the US Food and Drug Administration (FDA) to treat chronic myeloid leukemia, improved ...

Lewy bodies are a hallmark of Parkinson's disease (PD) and other related neurological conditions. Understanding why and how they develop is critical to developing better treatments. A study from The ...

Lewy bodies are a hallmark of Parkinson’s disease (PD) and other related neurological conditions. The presence of Lewy bodies in the brain is considered a “pathologic certainty” of Parkinson ...

Nilotinib (Tasigna) — a drug for myeloid leukemia — improved biomarkers and cognitive outcomes in study participants with dementia with Lewy bodies, a new study finds.

In November 2016, aged 60, Des finally had an answer – a formal diagnosis of dementia with Lewy bodies (DLB). “Until then, I had the common view of dementia, that it starts with memory loss ...

Opens in a new tab or window The chronic myeloid leukemia drug nilotinib (Tasigna) improved biomarkers and cognitive outcomes in people with dementia with Lewy bodies (DLB), a small phase II trial ...